Repare Therapeutics
Repare Therapeutics Inc. · RPTX (NASDAQ) · Montreal, QC · Pharmaceuticals
Latest R&D (CAD)
$158.8M
Period ended 2024-12-31
Revenue (CAD)
—
Intensity —
R&D by fiscal period
2024
$158.8M
2023
$180.3M
2022
$154.9M
2021
$112.9M
2020
$53.8M
2019
$27.9M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2024-12-31 | $158,815,982 | — | $115,941,000 USD | 10-K | SEC EDGAR |
| 2023-12-31 | $180,310,472 | — | $133,593,000 USD | 10-K | SEC EDGAR |
| 2022-12-31 | $154,940,586 | — | $119,066,000 USD | 10-K | SEC EDGAR |
| 2021-12-31 | $112,873,915 | — | $90,047,000 USD | 10-K | SEC EDGAR |
| 2020-12-31 | $53,782,077 | — | $40,091,000 USD | 10-K | SEC EDGAR |
| 2019-12-31 | $27,858,266 | — | $20,995,000 USD | 10-K | SEC EDGAR |